Agios Pharmaceuticals (NASDAQ:AGIO) CFO Cecilia Jones Sells 3,141 Shares

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) CFO Cecilia Jones sold 3,141 shares of the firm’s stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $34.71, for a total value of $109,024.11. Following the transaction, the chief financial officer directly owned 54,998 shares in the company, valued at approximately $1,908,980.58. This represents a 5.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Agios Pharmaceuticals Stock Down 1.1%

Shares of NASDAQ:AGIO opened at $34.80 on Tuesday. The stock has a market cap of $2.04 billion, a PE ratio of -4.89 and a beta of 0.79. The company’s fifty day moving average is $29.00 and its 200 day moving average is $32.12. Agios Pharmaceuticals, Inc. has a 52 week low of $22.24 and a 52 week high of $46.00.

Trending Headlines about Agios Pharmaceuticals

Here are the key news stories impacting Agios Pharmaceuticals this week:

• Positive Sentiment: JPMorgan raised its price target on AGIO from $31 to $36 (maintaining a “neutral” rating), signaling modest analyst upside and providing some support for the share price. Article Link
• Neutral Sentiment: Agios scheduled its Q1 2026 earnings conference call and webcast for April 29, 2026 — a standard corporate update that can trigger short-term moves around results but is informational until the release. Press Release
• Neutral Sentiment: Insider sale — Tsveta Milanova sold 3,262 shares at ~$34.71 under a pre-arranged Rule 10b5-1 plan to cover tax withholding from equity vesting; trade reduces her holdings ~6.5% but was routine and pre-planned. SEC Filing
• Neutral Sentiment: Insider sale — CFO Cecilia Jones sold 3,141 shares at ~$34.71 via a Rule 10b5-1 plan to cover taxes on vested awards; holding reduced ~5.4%. Investors typically view such planned tax-related sales as neutral. SEC Filing
• Neutral Sentiment: Insider sale — Sarah Gheuens sold 2,940 shares at ~$34.71 under a pre-arranged plan to cover tax withholding; position decreased ~3.5%. SEC Filing
• Neutral Sentiment: Insider sale — James William Burns sold 3,280 shares at ~$34.71 via a Rule 10b5-1 plan to cover tax obligations; holdings down ~6.2%. SEC Filing

Hedge Funds Weigh In On Agios Pharmaceuticals

Hedge funds have recently modified their holdings of the company. AQR Capital Management LLC increased its stake in shares of Agios Pharmaceuticals by 66.8% during the first quarter. AQR Capital Management LLC now owns 51,489 shares of the biopharmaceutical company’s stock valued at $1,498,000 after buying an additional 20,625 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Agios Pharmaceuticals by 7.2% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,327 shares of the biopharmaceutical company’s stock valued at $1,274,000 after buying an additional 2,920 shares during the period. NewEdge Advisors LLC purchased a new position in shares of Agios Pharmaceuticals during the first quarter valued at approximately $40,000. Goldman Sachs Group Inc. increased its stake in shares of Agios Pharmaceuticals by 16.1% during the first quarter. Goldman Sachs Group Inc. now owns 658,652 shares of the biopharmaceutical company’s stock valued at $19,299,000 after buying an additional 91,482 shares during the period. Finally, Woodline Partners LP purchased a new position in shares of Agios Pharmaceuticals during the first quarter valued at approximately $597,000.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on AGIO shares. Bank of America lifted their target price on shares of Agios Pharmaceuticals from $32.00 to $34.00 and gave the stock a “buy” rating in a research report on Wednesday, December 24th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Agios Pharmaceuticals in a research note on Friday, March 27th. The Goldman Sachs Group lifted their price target on Agios Pharmaceuticals from $28.00 to $32.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 1st. Citigroup lifted their price target on Agios Pharmaceuticals from $38.00 to $46.00 and gave the stock a “buy” rating in a research note on Thursday, March 5th. Finally, HC Wainwright lifted their price target on Agios Pharmaceuticals from $62.00 to $65.00 and gave the stock a “buy” rating in a research note on Thursday, February 12th. Six analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Agios Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $42.67.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.